Statistics for Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting

Total visits

views
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting 0

Total visits per month

views
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 0
May 2025 0